Want to see JP:4547 full AI Analyst Report?
Kissei Pharmaceutical Co (4547) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kps-0373 | Spinocerebellar Degeneration | Phase III | Recruiting | Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration | Jun 25, 2025 | ― |
| Klh-2109, Leuprorelin Acetate | Endometriosis | Phase III | Recruiting | A Clinical Study of KLH-2109 in Patients With Endometriosis | Jun 03, 2025 | ― |
| Kdt-3594 | Parkinson Disease | Phase II | Recruiting | A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | Nov 26, 2024 | ― |
| Ksp-0243 | Colitis, Ulcerative | Phase II | Completed | An Early Phase 2 Clinical Study of KSP-0243 | Mar 02, 2023 | ― |
| Klh-2109 | Uterine Fibroids (Mesh Heading: Leiomyoma) | Phase III | Completed | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | Jun 27, 2022 | ― |
| Leuprorelin, Klh-2109 | Uterine Fibroids (Mesh Heading: Leiomyoma) | Phase III | Completed | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | Jun 27, 2022 | ― |
| Mr13a9 | Uremic Pruritus | Phase III | Completed | A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | Jan 13, 2021 | ― |
| 75 Mg Linzagolix Tablet, 200 Mg Linzagolix Tablet, Add-Back Capsule (E2 1 Mg / Neta 0.5 Mg) | Endometriosis | Phase III | Terminated | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain | Apr 29, 2020 | ― |
| 75 Mg Linzagolix Tablet, 200 Mg Linzagolix Tablet, Add-Back Capsule (E2 1 Mg / Neta 0.5 Mg) | Endometriosis | Phase III | Completed | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) | Apr 03, 2020 | ― |
| R788 | Idiopathic Thrombocytopenic Purpura | Phase III | Completed | A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 | Oct 15, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kps-0373 | Phase III | Spinocerebellar Degeneration | Recruiting | Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration | Jun 25, 2025 | ― |
| Klh-2109, Leuprorelin Acetate | Phase III | Endometriosis | Recruiting | A Clinical Study of KLH-2109 in Patients With Endometriosis | Jun 03, 2025 | ― |
| Kdt-3594 | Phase II | Parkinson Disease | Recruiting | A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | Nov 26, 2024 | ― |
| Ksp-0243 | Phase II | Colitis, Ulcerative | Completed | An Early Phase 2 Clinical Study of KSP-0243 | Mar 02, 2023 | ― |
| Klh-2109 | Phase III | Uterine Fibroids (Mesh Heading: Leiomyoma) | Completed | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | Jun 27, 2022 | ― |
| Leuprorelin, Klh-2109 | Phase III | Uterine Fibroids (Mesh Heading: Leiomyoma) | Completed | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | Jun 27, 2022 | ― |
| Mr13a9 | Phase III | Uremic Pruritus | Completed | A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | Jan 13, 2021 | ― |
| 75 Mg Linzagolix Tablet, 200 Mg Linzagolix Tablet, Add-Back Capsule (E2 1 Mg / Neta 0.5 Mg) | Phase III | Endometriosis | Terminated | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain | Apr 29, 2020 | ― |
| 75 Mg Linzagolix Tablet, 200 Mg Linzagolix Tablet, Add-Back Capsule (E2 1 Mg / Neta 0.5 Mg) | Phase III | Endometriosis | Completed | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) | Apr 03, 2020 | ― |
| R788 | Phase III | Idiopathic Thrombocytopenic Purpura | Completed | A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 | Oct 15, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Kissei Pharmaceutical Co (JP:4547) have in its pipeline
Kissei Pharmaceutical Co JP:4547 is currently developing the following drugs: Kps-0373, Klh-2109, Leuprorelin Acetate, Kdt-3594, Ksp-0243, Klh-2109, Leuprorelin, Klh-2109, Mr13a9, 75 Mg Linzagolix Tablet, 200 Mg Linzagolix Tablet, Add-Back Capsule (E2 1 Mg / Neta 0.5 Mg), R788. These drug candidates are in various stages of clinical development as the company works toward FDA approval.